Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis
Advanced Materials · 2024-04 · 36 (16)
DOI: 10.1002/adma.202311474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 12.01.2024. Verfasst von Ling-Feng Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Endothelial Cells, Nanoparticles, Liposomes. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
During liver fibrogenesis, the reciprocal crosstalk among capillarized liver sinusoidal endothelial cells (LSECs), activated hepatic stellate cells (HSCs), and dysfunctional hepatocytes constructs a self‐amplifying vicious cycle, greatly exacerbating the disease condition and weakening therapeutic effect. Limited by the malignant cellular interactions, the previous single‐cell centric treatment approaches show unsatisfactory efficacy and fail to meet clinical demand. Herein, a vicious cycle‐breaking strategy is proposed to target and repair pathological cells separately to terminate the malignant progression of liver fibrosis. Chondroitin sulfate‐modified and vismodegib‐loaded nanoparticles (CS‐NPs/VDG) are designed to efficiently normalize the fenestrae phenotype of LSECs and restore HSCs to quiescent state by inhibiting Hedgehog signaling pathway. In addition, glycyrrhetinic acid‐modified and silybin‐loaded nanoparticles (GA‐NPs/SIB) are prepared to restore hepatocytes function by relieving oxidative stress. The results show successful interruption of vicious cycle as well as distinct fibrosis resolution in two animal models through multiregulation of the pathological cells. This work not only highlights the significance of modulating cellular crosstalk but also provides a promising avenue for developing antifibrotic regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.
- College of Pharmacy, Yanbian University, Yanji, 133002, China.
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing, 210009, China.
ORCID-Profile: Hu-Lin Jiang
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Zhang, L. F., Deng, W. Q., Huang, Q. W., Zhang, J. J., Wang, Y., Zhou, T. J., Xing, L., & Jiang, H. L. (2024). Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis. Advanced Materials, 36(16). https://doi.org/10.1002/adma.202311474
Vancouver
Zhang LF, Deng WQ, Huang QW, Zhang JJ, Wang Y, Zhou TJ, et al. Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis. Advanced Materials. 2024;36(16). doi:10.1002/adma.202311474
BibTeX
@article{Zhang2024,
author = {Zhang, Ling-Feng and Deng, Wen-Qi and Huang, Qing-Wen and Zhang, Jiao-Jiao and Wang, Yi and Zhou, Tian-Jiao and Xing, Lei and Jiang, Hu-Lin},
title = {Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {16},
doi = {10.1002/adma.202311474}
}
EUVIMED